# Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

> **NCT03294694** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
- HER2-Negative Breast Cancer
- Metastatic Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** PDR001
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03294694
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-08
- **Primary completion:** 2020-10-14
- **Final completion:** 2020-10-14
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Safety Implications
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03294694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03294694, "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03294694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*